西布曲明
减肥
医学
安慰剂
血糖性
置信区间
科克伦图书馆
肥胖
随机对照试验
内科学
糖尿病
内分泌学
替代医学
病理
作者
David Arterburn,Paul K. Crane,David L. Veenstra
出处
期刊:Archives of internal medicine
[American Medical Association]
日期:2004-05-10
卷期号:164 (9): 994-994
被引量:252
标识
DOI:10.1001/archinte.164.9.994
摘要
Background: The primary goal of weight loss is to prevent or reduce obesity-associated morbidity and mortality by improving cardiovascular and metabolic risk factors.We conducted a systematic review to assess the efficacy and safety of sibutramine hydrochloride for weight loss.Methods: In April 2002, we searched MEDLINE, EMBASE, the Cochrane Library, and 7 other computerized bibliographic search tools using the keywords "sibutramine," "Meridia," and "Reductil" (in all languages and all available years).The authors and the manufacturer were contacted.We reviewed randomized placebo-controlled trials of sibutramine, 10 to 20 mg/d, in obese adults.Methodological quality was assessed.Results: A total of 29 trials had sufficient data for analysis after including unpublished data from 10 authors.The summary mean differences in weight loss, sibutramine minus placebo, for the 3-month and 1-year trials were -2.78 kg (95% confidence interval, -2.26 to -3.29 kg)
科研通智能强力驱动
Strongly Powered by AbleSci AI